Skip to main content
ONCOSIL MEDICAL LTD logo

ONCOSIL MEDICAL LTD — Investor Relations & Filings

Ticker · OSL ISIN · AU000000OSL3 ASX Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country AU Australia
Listing ASX OSL

About ONCOSIL MEDICAL LTD

https://www.oncosil.com

OncoSil Medical Ltd is a medical technology company focused on the development and commercialization of localized treatments for patients with unresectable cancers. The company's lead product, OncoSil, is a targeted radioactive isotope microparticle therapy designed to deliver a concentrated dose of beta radiation directly into solid tumors. It is primarily indicated for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. The device utilizes Phosphorus-32 microparticles administered via endoscopic ultrasound-guided fine-needle injection, providing a localized brachytherapy approach intended to reduce tumor volume and improve surgical resectability. OncoSil Medical holds regulatory approvals in multiple jurisdictions, including the CE Mark for use in the European Union and the United Kingdom, and continues to evaluate clinical applications for other solid tumor types.

Recent filings

Filing Released Lang Actions
OncoSil progresses HDE with US FDA 3 pages 387.2KB
Regulatory Filings Classification · 92% confidence The document is an ASX announcement updating investors on the status of OncoSil’s FDA Humanitarian Device Exemption application—a regulatory milestone rather than a financial report, management change, dividend notice, or call transcript. It contains no detailed financial statements or governance materials, but is a routine regulatory announcement. This falls under the general Regulatory Filings category (RNS).
2026-06-09 English
US FDA HDE and TRIPP-FFX Study Presentation 20 pages 1.1MB
Investor Presentation Classification · 90% confidence The document is headed “ASX Announcement” and explicitly states it is releasing an “Investor Presentation” and contains slide‐style content (FDA update, trial initial results, strategy/pathway). It is not a financial report, earnings release, or brief factsheet, but a detailed presentation for investors. This matches the definition of an Investor Presentation (Code: IP).
2026-06-09 English
TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints 7 pages 457.8KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement detailing clinical trial results and forward-looking regulatory and commercial plans. It contains no financial statements, earnings data, management changes, share transactions, or formal investor presentation materials. It is a general regulatory announcement to the stock exchange that does not fit other specific categories, making it a fallback Regulatory Filing.
2026-06-09 English
Trading Halt 2 pages 454.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX market announcement requesting a trading halt under ASX Listing Rule 17.1. It does not present financial results, board changes, share issues, or other distinct category content. It is a general compliance/regulatory announcement to the exchange. Therefore it falls into the fallback category Regulatory Filings (RNS).
2026-06-04 English
TRIPP FFX Clinical Trial to Report Results in June 2 pages 282.9KB
Regulatory Filings Classification · 45% confidence The document is an ASX announcement providing an operational update on clinical trial result timing. It does not present financial results, management changes, share transactions, dividend information, or any formal report. It is not an investor presentation nor a regulatory form with substantive financial data. It is a general corporate announcement and thus falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-06-01 English
Key New Ethics Approval for Italian Patient Registry 3 pages 358.0KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement regarding ethics committee approval for a patient registry and procurement framework in Italy. It is not a financial report (e.g., Annual Report, Interim Report), nor does it announce dividends, capital changes, M&A, or contain detailed financial data. It is a general regulatory/compliance update and does not attach or publish a longer report. This fits best into the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-05-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.